We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Immunomedics Inc | NASDAQ:IMMU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 87.86 | 88.00 | 83.47 | 0 | 01:00:00 |
18 August 2017
Immunicum AB: Interim Report Q2 - Corporate Update and OutlookImmunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing an off-the-shelf immune system primer against a range of solid tumors, today announced its financial results and a corporate update for the second quarter 2017.
CEO Statement - Second quarterOver the second quarter, Immunicum has advanced on several fronts that will be critical for positioning Immunicum and our allogeneic cell-based cancer therapy ilixadencel for success. Furthermore, I am very pleased that we have completed our internal strategic analysis on the next phase of ilixadencel's clinical development program. We have designed it with a clear focus to increase the number of key value inflection points and expand the indications and regulatory opportunities for the product in the evolving cancer therapeutic landscape. Based on applicability in a variety of solid tumors, its potential synergistic effects with other cancer therapies such as PD-1/PD-L1 inhibitors and its encouraging safety profile, we have now defined our vision to increase the program's value. A more in-depth discussion of the plan is included in the second quarter report and as the next step, we are currently considering different funding options to enable the implementation of the plan.
Immunicum's progress in the second quarter also includes the continued advancement of our ongoing clinical studies in renal cell carcinoma, HCC and GIST. In the ongoing Phase II MERECA study, in renal cell carcinoma a total of 68 patients at 28 centers in eight European countries and the US have been enrolled so far. The enrollment of the first patient in the United States is an important achievement for us. Although the process has been slower than anticipated, the current expectation is that we will complete the enrollment for the MERECA trial in the second half of this year. Two additional important highlights of the past quarter also include the publication in the Journal for ImmunoTherapy of Cancer of the complete results of ilixadencel's first clinical trial in metastatic Renal Cell Carcinoma (mRCC) and approval of the International Nonproprietary Name (INN), ilixadencel, for our lead program INTUVAX®. The described progress is a testament to the commitment of the Immunicum team to bring this therapy to patients and deliver long-term value to our shareholders.
We remain, as always, committed to our shareholders as we open the next chapter in Immunicum's corporate development efforts to harness ilixadencel's full potential. Over the past year, we have seen strong progress in our clinical development programs, which make us confident that we have chosen the right direction for ilixadencel. These are truly exciting times for me as a CEO and the whole team at Immunicum as we position the company into a path of measurable success in the clinic and for patients. I look forward to providing regular updates on our plans and achievements in the coming months.
Carlos de Sousa
President and CEO
Second quarter (April to June) 2017 Compared with the Same period in 2016
The full quarterly report is available on:
http://immunicum.se/investors/financial-reports/
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg@halvarsson.se
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
The information is such information that Immunicum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company's contact person on August 18, 2017 at 08.00 CET.
About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com |
1 Year Immunomedics Chart |
1 Month Immunomedics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions